Rilonacept
Mechanism :
Rilonacept reduces inflammation by binding to IL-1ß (some binding of IL-1a and IL-1 receptor antagonist) and preventing interaction with cell surface receptors.
Indication :
- For the treatment of cryopyrin-associated periodic syndromes
- Familial cold autoinflammatory syndrome
- Muckle-Wells syndrome in children 12 years and older.
Contraindications :
No contraindications.
Dosing :
≥12 years:
Initial 4.4 mg/kg SC (Maximum dose: 320 mg and not to exceed 160 mg per injection. If exceeding 160 mg, give as separate injections at 2 different sites). Maintenance: 2.2 mg/kg (Maximum dose: 160 mg) once weekly. Begin maintenance dose 1 week following loading dose.
Adverse Effect :
Antibody development, increased susceptibility to infections, injection site reactions, hypoesthesia.
Interaction :
Anti-TNF Agents: May enhance the adverse/toxic effect of Rilonacept.
Live Vaccines: Immunosuppressants may enhance the adverse/toxic effect of Live Vaccines.
Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity.
Hepatic Dose :
No dose adjustment recommended.